Skip to Content
Merck
CN

93304

Trizma® base

≥99.0% (T)

Synonym(s):

2-Amino-2-(hydroxymethyl)-1,3-propanediol, THAM, Tris base, Tris(hydroxymethyl)aminomethane, Trometamol

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
NH2C(CH2OH)3
CAS Number:
77-86-1
Molecular Weight:
121.14
EC Number:
201-064-4
UNSPSC Code:
12161700
MDL number:
MFCD00004679
Beilstein/REAXYS Number:
741883

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

aminopeptidase substrate

assay

≥99.0% (T)

form

crystalline

loss

≤1% loss on drying, 110 °C

color

white to very faintly yellow

useful pH range

7-9

pKa (25 °C)

8.1

bp

219-220 °C/10 mmHg (lit.)

mp

167-172 °C (lit.)

solubility

H2O: 1 M at 20 °C, clear

SMILES string

NC(CO)(CO)CO

InChI

1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2

InChI key

LENZDBCJOHFCAS-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Other Notes

The pH values of all buffers are temperature- and concentration-dependent. For Tris buffers, pH increases about 0.03 unit per °C decrease in temperature, and decreases 0.03-0.05 unit per ten-fold dilution.
For precise applications, use a carefully calibrated pH meter with a glass/calomel combination electrode.

Legal Information

Trizma is a registered trademark of Merck KGaA, Darmstadt, Germany

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sean Ekins et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(12), 2302-2308 (2010-09-17)
Drug-induced liver injury (DILI) is one of the most important reasons for drug development failure at both preapproval and postapproval stages. There has been increased interest in developing predictive in vivo, in vitro, and in silico models to identify compounds
Nigel Greene et al.
Chemical research in toxicology, 23(7), 1215-1222 (2010-06-18)
Drug-induced liver injury is a major issue of concern and has led to the withdrawal of a significant number of marketed drugs. An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential
Zhichao Liu et al.
PLoS computational biology, 7(12), e1002310-e1002310 (2011-12-24)
Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be translated

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service